{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T21:03:18Z","timestamp":1771362198456,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Burns"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.burns.2025.107848","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T23:45:18Z","timestamp":1767051918000},"page":"107848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-like peptide-1 receptor agonists after recent burn injury are associated with lower rates of infection, mortality, and opioid prescriptions"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8278-1259","authenticated-orcid":false,"given":"Matthew Q.","family":"Dao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6720-8250","authenticated-orcid":false,"given":"Anika Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7956-2393","authenticated-orcid":false,"given":"Sarah","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Won","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Laspro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9410-6030","authenticated-orcid":false,"given":"T. Justin","family":"Gillenwater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9018-045X","authenticated-orcid":false,"given":"Haig A.","family":"Yenikomshian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2176-7274","authenticated-orcid":false,"given":"Maxwell B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.burns.2025.107848_bib1","article-title":"Pathophysiology and management of burn injury-induced pain","volume":"10","author":"You","year":"2025","journal-title":"Burns Open Int Open Access J Burn Inj"},{"issue":"4","key":"10.1016\/j.burns.2025.107848_bib2","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/CCM.0000000000000790","article-title":"Morbidity and survival probability in burn patients in modern burn care","volume":"43","author":"Jeschke","year":"2015","journal-title":"Crit Care Med"},{"key":"10.1016\/j.burns.2025.107848_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.1026152","article-title":"Researches on cognitive sequelae of burn injury: Current status and advances","volume":"16","author":"Xie","year":"2022","journal-title":"Front Neurosci"},{"key":"10.1016\/j.burns.2025.107848_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/burnst\/tkaa047","article-title":"The pathogenesis and diagnosis of sepsis post burn injury","volume":"9","author":"Zhang","year":"2021","journal-title":"Burns Trauma"},{"issue":"3","key":"10.1016\/j.burns.2025.107848_bib5","first-page":"466","article-title":"Current concepts related to hypertrophic scarring in burn injuries","volume":"24","author":"Chiang","year":"2016","journal-title":"Wound Repair Regen Publ Wound Heal Soc Eur Tissue Repair Soc"},{"issue":"10052","key":"10.1016\/j.burns.2025.107848_bib6","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(16)31406-4","article-title":"Hypertrophic scarring: the greatest unmet challenge after burn injury","volume":"388","author":"Finnerty","year":"2016","journal-title":"Lancet Lond Engl"},{"issue":"6","key":"10.1016\/j.burns.2025.107848_bib7","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/jbcr\/iraa119","article-title":"American burn association guidelines on the management of acute pain in the adult burn patient: a review of the literature, a compilation of expert opinion, and next steps","volume":"41","author":"Romanowski","year":"2020","journal-title":"J Burn Care Res Publ Am Burn Assoc"},{"issue":"4","key":"10.1016\/j.burns.2025.107848_bib8","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.burns.2021.07.018","article-title":"Opioid dependence and treatment outcomes among patients with burn injury","volume":"48","author":"Peluso","year":"2022","journal-title":"Burns J Int Soc Burn Inj"},{"issue":"5","key":"10.1016\/j.burns.2025.107848_bib9","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/jbcr\/iraa088","article-title":"Multimodal analgesia and discharge opioid requirements in burn patients","volume":"41","author":"Wright","year":"2020","journal-title":"J Burn Care Res Publ Am Burn Assoc"},{"issue":"22","key":"10.1016\/j.burns.2025.107848_bib10","doi-asserted-by":"crossref","first-page":"16357","DOI":"10.3390\/ijms242216357","article-title":"An overview of recent developments in the management of burn injuries","volume":"24","author":"Radzikowska-B\u00fcchner","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.burns.2025.107848_bib11","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/14656566.2018.1551880","article-title":"Novel pharmacotherapy for burn wounds: what are the advancements","volume":"20","author":"Hamblin","year":"2019","journal-title":"Expert Opin Pharm"},{"issue":"2","key":"10.1016\/j.burns.2025.107848_bib12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/jbcr\/irae189","article-title":"The emerging role of GLP-1 agonists in burn care: what do we know?","volume":"46","author":"Manasyan","year":"2025","journal-title":"J Burn Care Res Publ Am Burn Assoc"},{"key":"10.1016\/j.burns.2025.107848_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.burns.2025.107848_bib14","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/SLA.0000000000006614","article-title":"Association of perioperative glucagon-like peptide-1 receptor agonist use and postoperative outcomes","volume":"281","author":"Aschen","year":"2025","journal-title":"Ann Surg"},{"issue":"9","key":"10.1016\/j.burns.2025.107848_bib15","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.metabol.2013.04.010","article-title":"GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC Pathways","volume":"62","author":"Aronis","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.burns.2025.107848_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.997578","article-title":"GLP-1 receptor agonist as a modulator of innate immunity","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.burns.2025.107848_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2024.114622","article-title":"Glucagon-like peptide 1 agonist and effects on reward behaviour: a systematic review","volume":"283","author":"Badulescu","year":"2024","journal-title":"Physiol Behav"},{"key":"10.1016\/j.burns.2025.107848_bib18","article-title":"GLP-1 receptor agonists: a novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review","volume":"35","author":"Aoun","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"issue":"9","key":"10.1016\/j.burns.2025.107848_bib19","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s00125-017-4330-3","article-title":"The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype","volume":"60","author":"Vinu\u00e9","year":"2017","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.burns.2025.107848_bib20","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2106\/JBJS.24.00468","article-title":"Glucagon-like peptide-1 receptor agonists decrease medical and surgical complications in morbidly obese patients undergoing primary TKA","volume":"107","author":"Kim","year":"2025","journal-title":"J Bone Jt Surg Am"},{"issue":"1","key":"10.1016\/j.burns.2025.107848_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/thorax-2024-221906","article-title":"Comparative estimate of glucose-lowering therapies on risk of incident pneumonia and severe sepsis: an analysis of real-world cohort data","volume":"80","author":"Henney","year":"2024","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.burns.2025.107848_bib22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/cells12030345","article-title":"The complexity of the post-burn immune response: an overview of the associated local and systemic complications","volume":"12","author":"Korkmaz","year":"2023","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.burns.2025.107848_bib23","first-page":"42","article-title":"A review of glucagon-like peptide-1 in dermatology","volume":"18","author":"Patino","year":"2025","journal-title":"J Clin Aesthetic Dermatol"},{"issue":"1","key":"10.1016\/j.burns.2025.107848_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/immuno5010011","article-title":"Anti-inflammatory and anti-oxidative effects of GLP1-RAs and SGLT2i: the guiding star towards cardiovascular protection in type 2 diabetes","volume":"5","author":"Marcon","year":"2025","journal-title":"Immuno"},{"issue":"1","key":"10.1016\/j.burns.2025.107848_bib25","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","article-title":"The changing opioid crisis: development, challenges and opportunities","volume":"26","author":"Volkow","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.burns.2025.107848_bib26","series-title":"Opioid Use Disorder: Evaluation and Management","author":"Dydyk","year":"2025"},{"issue":"4","key":"10.1016\/j.burns.2025.107848_bib27","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bph.15682","article-title":"Glucagon-like peptide-1 (GLP-1) signalling in the brain: from neural circuits and metabolism to therapeutics","volume":"179","author":"Kabahizi","year":"2022","journal-title":"Br J Pharm"},{"issue":"5","key":"10.1016\/j.burns.2025.107848_bib28","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3390\/biom15050622","article-title":"Therapeutic effects of GLP-1 receptor agonists and DPP-4 inhibitors in neuropathic pain: mechanisms and clinical implications","volume":"15","author":"Kuthati","year":"2025","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.burns.2025.107848_bib29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s10194-025-01979-4","article-title":"Advances in GLP-1 receptor agonists for pain treatment and their future potential","volume":"26","author":"He","year":"2025","journal-title":"J Headache Pain"},{"issue":"4","key":"10.1016\/j.burns.2025.107848_bib30","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"Br J Pharm"},{"issue":"20","key":"10.1016\/j.burns.2025.107848_bib31","doi-asserted-by":"crossref","first-page":"6985","DOI":"10.1523\/JNEUROSCI.0115-14.2014","article-title":"Glucagon-like peptide-1 receptor activation in the nucleus accumbens core suppresses feeding by increasing glutamatergic AMPA\/kainate signaling","volume":"34","author":"Mietlicki-Baase","year":"2014","journal-title":"J Neurosci"},{"key":"10.1016\/j.burns.2025.107848_bib32","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.physbeh.2019.03.026","article-title":"Central GLP-1 Receptors: novel molecular targets for cocaine use disorder","volume":"206","author":"Hernandez","year":"2019","journal-title":"Physiol Behav"},{"issue":"4","key":"10.1016\/j.burns.2025.107848_bib33","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"11","key":"10.1016\/j.burns.2025.107848_bib34","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.3390\/nu12113304","article-title":"Glucagon-Like Peptide-1 (GLP-1) in the integration of neural and endocrine responses to stress","volume":"12","author":"Diz-Chaves","year":"2020","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.burns.2025.107848_bib35","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/add.16679","article-title":"The association between glucose-dependent insulinotropic polypeptide and\/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: a real-world data analysis","volume":"120","author":"Qeadan","year":"2025","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.burns.2025.107848_bib36","first-page":"563","article-title":"Life after Burn, Part II: substance Abuse, Relationship and Living Situation of Burn Survivors","volume":"58","author":"Smolle","year":"2022","journal-title":"Med"},{"issue":"3","key":"10.1016\/j.burns.2025.107848_bib37","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.bja.2023.12.003","article-title":"Long term opioid use after burn injury: a retrospective cohort study","volume":"132","author":"Jamal","year":"2024","journal-title":"BJA Br J Anaesth"},{"issue":"4","key":"10.1016\/j.burns.2025.107848_bib38","first-page":"1","article-title":"GLP-1 receptor agonists: a review of glycemic benefits and beyond","volume":"37","author":"Clark","year":"2024","journal-title":"JAAPA J Am Acad Physician Assist"},{"issue":"1","key":"10.1016\/j.burns.2025.107848_bib39","doi-asserted-by":"crossref","DOI":"10.1097\/SHK.0b013e3181af0494","article-title":"The role of hyperglycemia in burned patients: evidence-based studies","volume":"33","author":"Mecott","year":"2010","journal-title":"Shock"},{"issue":"2","key":"10.1016\/j.burns.2025.107848_bib40","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/BCR.0000000000000265","article-title":"Post-burn hypermetabolism: past, present and future","volume":"37","author":"Jeschke","year":"2016","journal-title":"J Burn Care Res Publ Am Burn Assoc"},{"issue":"5","key":"10.1016\/j.burns.2025.107848_bib41","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.surg.2010.11.017","article-title":"Effects of glucagon-like peptide 1 (GLP-1) on glycemia control and its metabolic consequence after severe thermal injury \u2013 studies in an animal model","volume":"149","author":"Shen","year":"2011","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.burns.2025.107848_bib42","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.tem.2012.11.008","article-title":"Glucagon-like peptide 1 and appetite","volume":"24","author":"Dailey","year":"2013","journal-title":"Trends Endocrinol Metab TEM"},{"issue":"1","key":"10.1016\/j.burns.2025.107848_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/jcsm.13677","article-title":"The effects of glucagon-like peptide-1 receptor agonists on mitochondrial function within skeletal muscle: a systematic review","volume":"16","author":"Old","year":"2025","journal-title":"J Cachex Sarcopenia Muscle"},{"issue":"10","key":"10.1016\/j.burns.2025.107848_bib44","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.burns.2025.107848_bib45","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1097\/BCR.0000000000000355","article-title":"Burns: pathophysiology of systemic complications and current management","volume":"38","author":"Nielson","year":"2017","journal-title":"J Burn Care Res"},{"issue":"5","key":"10.1016\/j.burns.2025.107848_bib46","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/j.1476-5381.2012.01971.x","article-title":"Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders","volume":"166","author":"Salcedo","year":"2012","journal-title":"Br J Pharm"},{"issue":"13","key":"10.1016\/j.burns.2025.107848_bib47","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3390\/cells11132023","article-title":"GLP-1 receptor agonists in neurodegeneration: neurovascular unit in the spotlight","volume":"11","author":"Monti","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.burns.2025.107848_bib48","series-title":"Textbook on Scar Management: State of the Art Management and Emerging Technologies","article-title":"Scar Formation: Cellular Mechanisms","author":"Darby","year":"2020"}],"updated-by":[{"DOI":"10.1016\/j.burns.2026.107909","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000}}],"container-title":["Burns"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305417925004784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305417925004784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:56:11Z","timestamp":1770252971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305417925004784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0305417925004784"],"URL":"https:\/\/doi.org\/10.1016\/j.burns.2025.107848","relation":{},"ISSN":["0305-4179"],"issn-type":[{"value":"0305-4179","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide-1 receptor agonists after recent burn injury are associated with lower rates of infection, mortality, and opioid prescriptions","name":"articletitle","label":"Article Title"},{"value":"Burns","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.burns.2025.107848","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd and ISBI. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107848"}}